Why Antipsychotics and Dementia May Not Mix

In lieu of potentially dangerous (and ineffective) antipsychotics, targeted therapies could be the answer to helping doctors and families ease dementia symptoms.

7:00 AM

Author | Kevin Joy

Research long ago identified the dangers of prescribing antipsychotic medications to dementia patients — and the Food and Drug Administration began including black box warnings on the two different classes of the drugs in the mid-2000s — but doctors and families still might not be fully aware of the implications of doing so.

Beyond such medicines being ineffective for treating the symptoms at hand, they can cause added health problems and even, as a 2015 study found, hasten death.

"For many behaviors, it's kind of like killing a fly with a cannon," says Helen Kales, M.D., a professor of psychiatry and director of the Program for Positive Aging at the University of Michigan and the co-author of the study. "People have side effects that worsen the behaviors, and you have to give them even more medication. You end up chasing your tail."

Nonpharmacological strategies to target problem behaviors and/or modify them by changing a patient's environmental factors or helping caregivers to problem-solve ought to be a first-line priority, says Kales, who echoed that point in a paper published last year in BMJ.

She spoke more about her ongoing research and the importance of such alternative methods.

Interview

What makes these drugs so problematic for dementia patients?

Kales: We know the risks of antipsychotics include movement disorders, diabetes and risk of stroke; cognition can worsen. Data from meta-analyses of randomized trials and multiple observational studies have shown these drugs are associated with increases in mortality. And the benefits as shown in randomized controlled trials are moderate at best.

Some might say that because the patient has dementia, a higher risk of mortality isn't concerning. But if you have a situation where the person didn't need the drug in the first place, that's really unnecessary.

Beyond that, you have cases where drugs are being used, sadly, for things where there is no data to suggest they work. If somebody is wandering off, there's no drug in the world to treat that except to sedate the person. A non-drug approach would be vastly preferred.

These non-drug approaches aren't really part of the medical-school curriculum. They should be a mainstay of treatment.

Helen Kales, M.D.

Why, then, do physicians prescribe them?

Kales: People are stuck between a rock and a hard place in a lot of practice settings.

On one hand, they're being told to reduce the use of such medications because of the bad side effects. On the other, they're confronted with patients who are suffering and families who are exhausted and burdened.

People simply aren't armed with many alternatives. These non-drug approaches aren't really part of the medical-school curriculum. They should be a mainstay of treatment.

Could you talk about the "DICE" model you helped create to encourage avoidance of these drugs?

Kales: What we tried to do with DICE is create a simple algorithm so someone could walk through the thinking process in approaching the problematic behavior.

Describe: We want to fully understand the behavior. Say, "Joe" is agitated. What do you mean by "agitated?" Is this yelling? Or physical movement? Resistance to care? Where is it occurring? What does it look like?

Investigate: In a nutshell, we're playing detective. If I'm trying to give Joe a bath, and he's crying out and swatting at me, is the temperature of the bathwater too hot or cold? Is he in pain? Many people with dementia are in pain, but can't tell us.

Create: What are some simple interventions we could try? Let's make sure the temperature is right before we put him in the bath; move him gradually. We could talk to his doctor about giving him Tylenol if pain is thought to be a factor.

Evaluate: We want to see what worked and what didn't work; what other things could the caregiver try? It's a collaborative problem-solving process.

How can family members and caretakers help doctors execute a plan?

Kales: Caregivers are more empowered than they think. They're on the front lines and have the most contact with people with dementia. Doctors should be asking them questions: "You know Joe; what is he like?" "What has worked in the past to calm him down?"

One of the best ways is training to spot behaviors, especially before they become too severe, and to implement simple interventions for things that might be triggers — a television blaring, people screaming.

That said, are there instances when antipsychotics might be appropriate?

Kales: We would never say never. It's really more about targeting medications for when they're absolutely needed — if there was aggression or psychosis with a chance of risk to the patient or other people, for example.

You're probably not going to be able to get a urine sample from someone to test for a urinary-tract infection if they're swinging at you. Medication can be used to temporarily calm things down so you can investigate.

The hope is always that it's a temporary situation. One of the things we have to keep in mind is that these symptoms come and go. It doesn't make sense to have someone on medication forever.


More Articles About:

Rounds Alzheimer's Disease Geriatric Psychiatric Treatment Neurological (Brain) Conditions
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

grey outline of a brain with the left side light grey and the right side dark grey and colorful puzzle pieces floating in and out of the brain
Health Lab

Troubling Trio: Many with Dementia Take Risky Combinations of Medicines

People with Alzheimer’s and other forms of dementia often receive medications for depression, anxiety, agitation, sleep problems, apathy and other behavioral issues. But combinations of three or more can be dangerous.
outline of head with pills in brain
Health Lab

These Drugs Carry Risks and May Not Help, But Many Dementia Patients Get Them Anyway

From opioids and antipsychotics to antidepressants and anxiety medicines, study looks at prescriptions among community-dwelling older adults with dementia.
David Diebold smiles as he rings the bell at the end of the HURT100.
Philanthropy News

Going the extra 100 miles

U-M Medical School student runs the HURT100 ultramarathon to raise funds for the Michigan Alzheimer's Disease Center and the Alzheimer's Association.
Elderly man stands outside in a snowy neighborhood. He is holding a white mug of coffee in his right hand and has his left hand in a coat pocket. He is staring ahead, presumably taking in the snowy scene around him.
Health Lab

Small daily activities may help ease dementia caregivers’ stress

University of Michigan research suggests engaging in positive activities can improve the mood and physical wellbeing of Alzheimer’s disease or related dementia caregivers.
Minding Memory with a microphone and a shadow of a microphone on a blue background
Minding Memory

Antipsychotic Use in Nursing Homes: Balancing Medication Safety, Policy, and Dementia Care

In this episode, Lauren Gerlach and Matt Davis speak with Theresa Shireman, PhD, Director of the Center for Gerontology and Healthcare Research and a Professor of Health Services, Policy and Practice and Epidemiology at the Brown University School of Public Health. Dr. Shireman’s research focuses on pharmaceutical policy, pharmacoepidemiology, health services research, and medication use among vulnerable populations. Dr. Shireman discusses her recent study, "Impact of Federal Antipsychotic Use Policy in Nursing Homes on New Diagnoses for Approved Indications in Dementia Residents," published in the Journal of the American Geriatrics Society. The study examines whether federal policies designed to reduce antipsychotic use in nursing homes were associated with increases in new diagnoses of conditions, such as schizophrenia, that exclude residents from publicly report antipsychotic quality measures. Using an interrupted time-series design, the researchers examined changes following the 2012 National Partnership to Improve Dementia Care and the 2015 addition of antipsychotic use to the Nursing home Five-Star Quality Rating System. They found that neither policy was associated with an increase in new exclusionary diagnossees, challenging concerns that nursing homes were increasingly assigning these diagnoses to circumvent restrictions on antipsychotic use. The conversation also explores the benefits and risks of antipsychotic medications for people living with dementia, including the potential for serious adverse effects such as sedation, falls, stroke, and increased mortality. Dr. Shireman discusses how public reporting and financial incentives can influence prescribing practices,the limitations of using a single quality measure to evaluate nursing home care, and the importance of balancing medication safety and residents’ individual needs. The discussion highlights the need for shared decision-making among clinicians, nursing home staff, residents, and families, as well as greater investment in staffing, resources, and nonpharmacological approaches to improve quality of life for people living with dementia. The transcript for this episode can be found here.
Minding memory above a microphone on a blue background
Minding Memory

Can Your Voice Reveal Early Signs of Alzheimer’s?

In this episode, Lauren & Matt speak with Neguine Rezaii, MD, an Assistant Professor of Neurology at Harvard Medical School and a Board-Certified Neuropsychiatrist at Mass General Hospital. Dr. Rezaii’s research focuses on using natural language processing and artificial intelligence to improve the detection and classification of neurodegenerative disorders. Dr. Rezaii talks about her recent study, “Voiceprints of Cognitive Impairment: Analyzing Digital Voice for Early Detection of Alzheimer’s and Related Dementias,” which explores how artificial intelligence can analyze short speech samples to identify subtle signs of cognitive impairment. The study used speech recordings from 120 individuals and found that features such as pauses, word choice and the specificity of language can help distinguish cognitive impairment and Alzheimer’s disease. The conversation also explores how a simple 30-second speech test could potentially be used in clinical settings to support earlier detection and monitoring of cognitive impairment, as well as the challenges and ethical considerations that come with using AI to analyze something as personal as a person’s voice.